NorthCrest Asset Manangement’s 10x Genomics TXG Stock Holding History

NorthCrest Asset Manangement’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$321K	Buy	+7,438	New	+$195K	0.01%	722

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

NorthCrest Asset Manangement's TXG Position: Q2 2026 in Review

NorthCrest Asset Manangement opened a new position in 10x Genomics (TXG) in Q2 2026: 7,438 shares worth $321K. The stake represents 0.01% of the portfolio and ranks #722 among its holdings.

392 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

NorthCrest Asset Manangement held 7,438 shares of 10x Genomics worth $321K as of Q2 2026.
10x Genomics was a new NorthCrest Asset Manangement position in Q2 2026.
10x Genomics made up 0.01% of NorthCrest Asset Manangement's portfolio in Q2 2026, its #722 holding.
392 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on NorthCrest Asset Manangement's 13F filing for Q2 2026, filed 15 Jul 2026.